Clinical Trials Browser

NCT07513129 2026-04-21

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

Phase 1 Not yet recruiting

18 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07221032 2026-04-14

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Not yet recruiting

12 enrolled

Plasma cell

Multiple Myeloma

NCT07485647 2026-03-20

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Phase 2 Not yet recruiting

50 enrolled

Plasma cell

Multiple Myeloma

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Phase 2 Not yet recruiting

50 enrolled

Plasma cell

Multiple Myeloma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Phase 2 Not yet recruiting

39 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07247097 2025-11-25

ELDORADO

Phase 2 Not yet recruiting

160 enrolled

Plasma cell

Multiple Myeloma

NCT06570915 2025-10-01

T-ALL-2024

Phase 2 Not yet recruiting

20 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07026604 2025-06-18

CCM-DS01

Phase EARLY_PHASE1 Not yet recruiting

10 enrolled

CNS

Hemangioma, Cavernous, Central Nervous System

NCT07015021 2025-06-11

DKPD

Phase NA Not yet recruiting

72 enrolled

Plasma cell

Multiple Myeloma

NCT06931704 2025-04-23

IFM 2024_06

Phase 2 Not yet recruiting

176 enrolled

Plasma cell

Multiple Myeloma

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Phase 1/2 Not yet recruiting

48 enrolled

Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05527340 2022-09-02

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Phase 2 Not yet recruiting

140 enrolled

Plasma cell

Multiple Myeloma

NCT05054478 2021-09-23

PCL-2

Phase 2 Not yet recruiting

29 enrolled

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell